Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Feb;95(2):446–455. doi: 10.1172/JCI117684

Specific inhibition of eIF-5A and collagen hydroxylation by a single agent. Antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries.

T A McCaffrey 1, K B Pomerantz 1, T A Sanborn 1, A M Spokojny 1, B Du 1, M H Park 1, J E Folk 1, A Lamberg 1, K I Kivirikko 1, D J Falcone 1, et al.
PMCID: PMC295486  PMID: 7860726

Abstract

Restenosis occurs in 35% of patients within months after balloon angioplasty, due to a fibroproliferative response to vascular injury. These studies describe a combined fibrosuppressive/antiproliferative strategy on smooth muscle cells cultured from human primary atherosclerotic and restenotic coronary arteries and from normal rat aortas. L-Mimosine suppressed the posttranslational hydroxylation of the precursors for collagen and for eukaryotic initiation factor-5A (eIF-5A) by directly inhibiting the specific protein hydroxylases involved, prolyl 4-hydroxylase (E.C. 1.14.11.2) and deoxyhypusyl hydroxylase (E.C. 1.14.99.29), respectively. Inhibition of deoxyhypusyl hydroxylation correlated with a dose-dependent inhibition of DNA synthesis. Inhibition of prolyl hydroxylation caused a dose-dependent reduction in the secretion of hydroxyproline-containing protein and decreased the formation of procollagen types I and III. The antifibroproliferative action could not be attributed to nonspecific or toxic effects of mimosine, appeared to be selective for the hydroxylation step in the biosynthesis of the procollagens and of eIF-5A, and was reversible upon removal of the compound. The strategy of targeting these two protein hydroxylases has important implications for the pathophysiology of restenosis and for the development of agents to control fibroproliferative diseases.

Full text

PDF
446

Images in this article

449Image
on p.449
452Image
on p.452

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbruzzese A., Hanauske-Abel H. M., Park M. H., Henke S., Folk J. E. The active site of deoxyhypusyl hydroxylase: use of catecholpeptides and their component chelator and peptide moieties as molecular probes. Biochim Biophys Acta. 1991 Apr 8;1077(2):159–166. doi: 10.1016/0167-4838(91)90053-3. [DOI] [PubMed] [Google Scholar]
  2. Abbruzzese A., Park M. H., Folk J. E. Deoxyhypusine hydroxylase from rat testis. Partial purification and characterization. J Biol Chem. 1986 Mar 5;261(7):3085–3089. [PubMed] [Google Scholar]
  3. Bashkin P., Doctrow S., Klagsbrun M., Svahn C. M., Folkman J., Vlodavsky I. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry. 1989 Feb 21;28(4):1737–1743. doi: 10.1021/bi00430a047. [DOI] [PubMed] [Google Scholar]
  4. Bidanset D. J., Guidry C., Rosenberg L. C., Choi H. U., Timpl R., Hook M. Binding of the proteoglycan decorin to collagen type VI. J Biol Chem. 1992 Mar 15;267(8):5250–5256. [PubMed] [Google Scholar]
  5. Björkerud S. Effects of transforming growth factor-beta 1 on human arterial smooth muscle cells in vitro. Arterioscler Thromb. 1991 Jul-Aug;11(4):892–902. [PubMed] [Google Scholar]
  6. Bonnet J., Garderes P. E., Aumailley M., Moreau C., Gouverneur G., Benchimol D., Crockett R., Larrue J., Bricaud H. Serum type III procollagen peptide levels in coronary artery disease (a marker of atherosclerosis). Eur J Clin Invest. 1988 Feb;18(1):18–21. doi: 10.1111/j.1365-2362.1988.tb01159.x. [DOI] [PubMed] [Google Scholar]
  7. Chessler S. D., Byers P. H. Defective folding and stable association with protein disulfide isomerase/prolyl hydroxylase of type I procollagen with a deletion in the pro alpha 2(I) chain that preserves the Gly-X-Y repeat pattern. J Biol Chem. 1992 Apr 15;267(11):7751–7757. [PubMed] [Google Scholar]
  8. Clowes A. W., Clowes M. M., Fingerle J., Reidy M. A. Kinetics of cellular proliferation after arterial injury. V. Role of acute distension in the induction of smooth muscle proliferation. Lab Invest. 1989 Mar;60(3):360–364. [PubMed] [Google Scholar]
  9. Cunliffe C. J., Franklin T. J., Hales N. J., Hill G. B. Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analogue N-oxaloglycine and its derivatives. J Med Chem. 1992 Jul 10;35(14):2652–2658. doi: 10.1021/jm00092a016. [DOI] [PubMed] [Google Scholar]
  10. Dartsch P. C., Bauriedel G., Schinko I., Weiss H. D., Höfling B., Betz E. Cell constitution and characteristics of human atherosclerotic plaques selectively removed by percutaneous atherectomy. Atherosclerosis. 1989 Dec;80(2):149–157. doi: 10.1016/0021-9150(89)90023-3. [DOI] [PubMed] [Google Scholar]
  11. Dartsch P. C., Voisard R., Bauriedel G., Höfling B., Betz E. Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary stenosing and restenosing lesions. Arteriosclerosis. 1990 Jan-Feb;10(1):62–75. doi: 10.1161/01.atv.10.1.62. [DOI] [PubMed] [Google Scholar]
  12. Dawson C. D., Jewell S., Driskell W. J. Liquid-chromatographic determination of total hydroxyproline in urine. Clin Chem. 1988 Aug;34(8):1572–1574. [PubMed] [Google Scholar]
  13. Desmoulière A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993 Jul;122(1):103–111. doi: 10.1083/jcb.122.1.103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Dunphy M. J., Bhide M. V., Smith D. J. Determination of hydroxyproline in tissue collagen hydrolysate by derivatization and isocratic reversed-phase high-performance liquid chromatography. J Chromatogr. 1987 Sep 25;420(2):394–397. doi: 10.1016/0378-4347(87)80195-0. [DOI] [PubMed] [Google Scholar]
  15. Falcone D. J., McCaffrey T. A., Haimovitz-Friedman A., Vergilio J. A., Nicholson A. C. Macrophage and foam cell release of matrix-bound growth factors. Role of plasminogen activation. J Biol Chem. 1993 Jun 5;268(16):11951–11958. [PubMed] [Google Scholar]
  16. Hanauske-Abel H. M., Günzler V. A stereochemical concept for the catalytic mechanism of prolylhydroxylase: applicability to classification and design of inhibitors. J Theor Biol. 1982 Jan 21;94(2):421–455. doi: 10.1016/0022-5193(82)90320-4. [DOI] [PubMed] [Google Scholar]
  17. Hanauske-Abel H. M., Park M. H., Hanauske A. R., Popowicz A. M., Lalande M., Folk J. E. Inhibition of the G1-S transition of the cell cycle by inhibitors of deoxyhypusine hydroxylation. Biochim Biophys Acta. 1994 Mar 31;1221(2):115–124. doi: 10.1016/0167-4889(94)90003-5. [DOI] [PubMed] [Google Scholar]
  18. Hanauske-Abel H. M. Prolyl 4-hydroxylase, a target enzyme for drug development. Design of suppressive agents and the in vitro effects of inhibitors and proinhibitors. J Hepatol. 1991;13 (Suppl 3):S8–S16. doi: 10.1016/0168-8278(91)90003-t. [DOI] [PubMed] [Google Scholar]
  19. Herrman J. P., Hermans W. R., Vos J., Serruys P. W. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part I). Drugs. 1993 Jul;46(1):18–52. doi: 10.2165/00003495-199346010-00003. [DOI] [PubMed] [Google Scholar]
  20. Hojima Y., van der Rest M., Prockop D. J. Type I procollagen carboxyl-terminal proteinase from chick embryo tendons. Purification and characterization. J Biol Chem. 1985 Dec 15;260(29):15996–16003. [PubMed] [Google Scholar]
  21. Kelly J. L., Sánchez A., Brown G. S., Chesterman C. N., Sleigh M. J. Accumulation of PDGF B and cell-binding forms of PDGF A in the extracellular matrix. J Cell Biol. 1993 Jun;121(5):1153–1163. doi: 10.1083/jcb.121.5.1153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kivirikko K. I., Myllylä R., Pihlajaniemi T. Protein hydroxylation: prolyl 4-hydroxylase, an enzyme with four cosubstrates and a multifunctional subunit. FASEB J. 1989 Mar;3(5):1609–1617. [PubMed] [Google Scholar]
  23. Lambert C. R., Leone J. E., Rowland S. M. Local drug delivery catheters: functional comparison of porous and microporous designs. Coron Artery Dis. 1993 May;4(5):469–475. [PubMed] [Google Scholar]
  24. MacLeod D. C., Strauss B. H., de Jong M., Escaned J., Umans V. A., van Suylen R. J., Verkerk A., de Feyter P. J., Serruys P. W. Proliferation and extracellular matrix synthesis of smooth muscle cells cultured from human coronary atherosclerotic and restenotic lesions. J Am Coll Cardiol. 1994 Jan;23(1):59–65. doi: 10.1016/0735-1097(94)90502-9. [DOI] [PubMed] [Google Scholar]
  25. Majamaa K., Günzler V., Hanauske-Abel H. M., Myllylä R., Kivirikko K. I. Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. J Biol Chem. 1986 Jun 15;261(17):7819–7823. [PubMed] [Google Scholar]
  26. Majamaa K., Hanauske-Abel H. M., Günzler V., Kivirikko K. I. The 2-oxoglutarate binding site of prolyl 4-hydroxylase. Identification of distinct subsites and evidence for 2-oxoglutarate decarboxylation in a ligand reaction at the enzyme-bound ferrous ion. Eur J Biochem. 1984 Jan 16;138(2):239–245. doi: 10.1111/j.1432-1033.1984.tb07907.x. [DOI] [PubMed] [Google Scholar]
  27. Majamaa K., Turpeenniemi-Hujanen T. M., Latipä P., Günzler V., Hanauske-Abel H. M., Hassinen I. E., Kivirikko K. I. Differences between collagen hydroxylases and 2-oxoglutarate dehydrogenase in their inhibition by structural analogues of 2-oxoglutarate. Biochem J. 1985 Jul 1;229(1):127–133. doi: 10.1042/bj2290127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Majesky M. W., Lindner V., Twardzik D. R., Schwartz S. M., Reidy M. A. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest. 1991 Sep;88(3):904–910. doi: 10.1172/JCI115393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. McCaffrey T. A., Falcone D. J., Du B. Transforming growth factor-beta 1 is a heparin-binding protein: identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF-beta 1. J Cell Physiol. 1992 Aug;152(2):430–440. doi: 10.1002/jcp.1041520226. [DOI] [PubMed] [Google Scholar]
  30. Paralkar V. M., Vukicevic S., Reddi A. H. Transforming growth factor beta type 1 binds to collagen IV of basement membrane matrix: implications for development. Dev Biol. 1991 Feb;143(2):303–308. doi: 10.1016/0012-1606(91)90081-d. [DOI] [PubMed] [Google Scholar]
  31. Park M. H., Chung S. I., Cooper H. L., Folk J. E. The mammalian hypusine-containing protein, eukaryotic initiation factor 4D. Structural homology of this protein from several species. J Biol Chem. 1984 Apr 10;259(7):4563–4565. [PubMed] [Google Scholar]
  32. Park M. H., Cooper H. L., Folk J. E. The biosynthesis of protein-bound hypusine (N epsilon -(4-amino-2-hydroxybutyl)lysine). Lysine as the amino acid precursor and the intermediate role of deoxyhypusine (N epsilon -(4-aminobutyl)lysine). J Biol Chem. 1982 Jun 25;257(12):7217–7222. [PubMed] [Google Scholar]
  33. Park M. H., Wolff E. C., Folk J. E. Hypusine: its post-translational formation in eukaryotic initiation factor 5A and its potential role in cellular regulation. Biofactors. 1993 May;4(2):95–104. [PubMed] [Google Scholar]
  34. Pickering J. G., Weir L., Rosenfield K., Stetz J., Jekanowski J., Isner J. M. Smooth muscle cell outgrowth from human atherosclerotic plaque: implications for the assessment of lesion biology. J Am Coll Cardiol. 1992 Nov 15;20(6):1430–1439. doi: 10.1016/0735-1097(92)90259-p. [DOI] [PubMed] [Google Scholar]
  35. Porreca E., Ucchino S., Di Febbo C., Di Bartolomeo N., Angelucci D., Napolitano A. M., Mezzetti A., Cuccurullo F. Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo. Arterioscler Thromb. 1994 Feb;14(2):299–304. doi: 10.1161/01.atv.14.2.299. [DOI] [PubMed] [Google Scholar]
  36. Pressley J. C., Wharton J. M., Tang A. S., Lowe J. E., Gallagher J. J., Prystowsky E. N. Effect of Ebstein's anomaly on short- and long-term outcome of surgically treated patients with Wolff-Parkinson-White syndrome. Circulation. 1992 Oct;86(4):1147–1155. doi: 10.1161/01.cir.86.4.1147. [DOI] [PubMed] [Google Scholar]
  37. Reis P. J., Tunks D. A., Hegarty M. P. Fate of mimosine administered orally to sheep and its effectiveness as a defleecing agent. Aust J Biol Sci. 1975 Dec;28(5-6):495–501. doi: 10.1071/bi9750495. [DOI] [PubMed] [Google Scholar]
  38. Rogers C., Karnovsky M. J., Edelman E. R. Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration. Circulation. 1993 Sep;88(3):1215–1221. doi: 10.1161/01.cir.88.3.1215. [DOI] [PubMed] [Google Scholar]
  39. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  40. Rønnov-Jessen L., Petersen O. W. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest. 1993 Jun;68(6):696–707. [PubMed] [Google Scholar]
  41. Schwartz S. M., Haudenschild C. C., Eddy E. M. Endothelial regneration. I. Quantitative analysis of initial stages of endothelial regeneration in rat aortic intima. Lab Invest. 1978 May;38(5):568–580. [PubMed] [Google Scholar]
  42. Stemerman M. B., Weinstein R., Rowe J. W., Maciag T., Fuhro R., Gardner R. Vascular smooth muscle cell growth kinetics in vivo in aged rats. Proc Natl Acad Sci U S A. 1982 Jun;79(12):3863–3866. doi: 10.1073/pnas.79.12.3863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Takahara S., Takahashi H. An amine-induced alopecia in mice. J Biochem. 1972 Jul;72(1):195–197. [PubMed] [Google Scholar]
  44. Timpl R. Proteoglycans of basement membranes. Experientia. 1993 May 15;49(5):417–428. doi: 10.1007/BF01923586. [DOI] [PubMed] [Google Scholar]
  45. Tschank G., Raghunath M., Günzler V., Hanauske-Abel H. M. Pyridinedicarboxylates, the first mechanism-derived inhibitors for prolyl 4-hydroxylase, selectively suppress cellular hydroxyprolyl biosynthesis. Decrease in interstitial collagen and Clq secretion in cell culture. Biochem J. 1987 Dec 15;248(3):625–633. doi: 10.1042/bj2480625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Vuori K., Pihlajaniemi T., Marttila M., Kivirikko K. I. Characterization of the human prolyl 4-hydroxylase tetramer and its multifunctional protein disulfide-isomerase subunit synthesized in a baculovirus expression system. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7467–7470. doi: 10.1073/pnas.89.16.7467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wolff E. C., Park M. H., Folk J. E. Cleavage of spermidine as the first step in deoxyhypusine synthesis. The role of NAD. J Biol Chem. 1990 Mar 25;265(9):4793–4799. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES